Jim Simons
RARE icon

Jim Simons’s Ultragenyx Pharmaceutical RARE Stock Holding History

Jim Simons’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.8M Buy
561,700
+195,600
+53% +$4.4M 0.02% 887
2025
Q4 		$8.42M Buy
366,100
+344,200
+1,572% +$11.3M 0.01% 1008
2025
Q3 		$659K Sell
21,900
-186,400
-89% -$5.59M ﹤0.01% 2683
2025
Q2 		$7.57M Sell
208,300
-91,300
-30% -$3.29M 0.01% 1258
2025
Q1 		$10.8M Buy
299,600
+44,900
+18% +$1.87M 0.02% 967
2024
Q4 		$10.7M Buy
254,700
+72,600
+40% +$3.6M 0.02% 979
2024
Q3 		$10.1M Buy
+182,100
New +$9.28M 0.02% 1030
2023
Q3 		– Sell
-19,600
Closed -$904K – 4023
2023
Q2 		$904K Buy
+19,600
New +$909K ﹤0.01% 2532
2022
Q1 		– Sell
-47,400
Closed -$3.99M – 4388
2021
Q4 		$3.99M Sell
47,400
-24,200
-34% -$1.97M 0.01% 1668
2021
Q3 		$6.46M Sell
71,600
-390,800
-85% -$35.3M 0.01% 1307
2021
Q2 		$44.1M Buy
462,400
+317,600
+219% +$33.1M 0.06% 376
2021
Q1 		$16.5M Buy
144,800
+50,000
+53% +$6.81M 0.02% 892
2020
Q4 		$13.1M Buy
+94,800
New +$11.2M 0.01% 989
2016
Q2 		– Sell
-54,400
Closed -$3.44M – 3477
2016
Q1 		$3.44M Buy
+54,400
New +$3.56M 0.01% 1895
2015
Q4 		– Sell
-3,200
Closed -$308K – 3401
2015
Q3 		$308K Buy
+3,200
New +$366K ﹤0.01% 2761

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Jim Simons's RARE Position: Q1 2026 in Review

Jim Simons increased its Ultragenyx Pharmaceutical (RARE) stake by 53% in Q1 2026, buying an estimated $4.4M and bringing the position to 561,700 shares worth $11.8M. The position accounts for 0.02% of the portfolio, ranked #887.

Jim Simons first reported a position in RARE in Q3 2015 and has held it in 15 quarters since. The position peaked at $44.1M in Q2 2021. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Jim Simons held 561,700 shares of Ultragenyx Pharmaceutical worth $11.8M as of Q1 2026.
  • Jim Simons bought 195,600 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $4.4M.
  • Ultragenyx Pharmaceutical made up 0.02% of Jim Simons's portfolio in Q1 2026, its #887 holding.
  • Jim Simons first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and has held it in 15 quarters since.
  • Jim Simons's Ultragenyx Pharmaceutical position peaked at $44.1M in Q2 2021.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.